March 10, 2015 -- An injectable drug to treat double chin in adults should be approved for sale in the United States, a Food and Drug Administration advisory panel says.
Kythera Biopharmaceuticals' treatment, called ATX-101, would offer a nonsurgical option for double chin, the Wall Street Journal reported.
The injectable drug -- which was tested in 19 clinical trials involving about 2,600 people -- is a formulation of a pure, non-animal derived deoxycholic acid that helps break down fat, according to the California-based company.
The FDA typically follows the recommendations of its advisory panels. If approval is granted, Kythera said sales of ATX-101 could begin in the second half of the year, WSJ reported.
source : Double Chin Drug Should be Approved: FDA Panel
